Jeremy Levin, Ovid Therapeutics CEO (Ovid website via YouTube)
July 2, 2024 11:01 AM EDT
People
R&D

Fol­low­ing a piv­otal tri­al fail and lay­offs, Ovid finds it­self in a fa­mil­iar spot

Max Gelman

Senior Editor

Last week, Ovid Ther­a­peu­tics dis­closed lay­off plans in an SEC fil­ing fol­low­ing a Phase 3 flop for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times